Source comparison
How Much Thymosin Alpha-1 Per Day Daily Dose: Clinical Trial Comparison
| Dosing Protocol | Study Population | Duration | Primary Outcome | CD4+ T-Cell Change | Injection Frequency | Professional Assessment ||—|—|—|—|—|—|| 1.6mg twice weekly | Chronic Hepatitis B (n=103) | 24 weeks | HBeAg seroconversion 36% vs 15% placebo | +18%
This comparison does not assign a generated winner or score.
- | Dosing Protocol | Study Population | Duration | Primary Outcome | CD4+ T-Cell Change | Injection Frequency | Professional Assessment ||—|—|—|—|—|—|| 1.6mg twice weekly | Chronic Hepatitis B (n=103) | 24 weeks | HBeAg seroconversion 36% vs 15% placebo | +18% from baseline at week 12 | 2× per week | Gold-standard protocol. Most clinical evidence supports this schedule for immune priming applications || 3.2mg twice weekly | NSCLC + chemotherapy (n=89) | 18 weeks | Severe neutropenia reduction 28% vs placebo | +22% from baseline at week 8 | 2× per week | Higher dose justified only in chemotherapy-induced immunosuppression. No added benefit in healthy immune baselines || 0.9mg daily | Chronic viral infection (n=47) | 12 weeks | Viral load reduction comparable to 1.6mg 2×/week | +16% from baseline at week 12 | 7× per week | Equivalent immune response to twice-weekly 1.6mg but 3.2× higher injection site reaction incidence. No clinical advantage || 1.6mg three times weekly | Vaccine response
- The clinical trial comparison shows that twice-weekly 1.6mg protocols deliver robust immune response across diverse populations. Higher frequencies increase injection burden without proportional outcome improvement. The exception: patients under active chemotherapy, where immune suppression depth may justify 3.2mg twice weekly.